Directed evolution

At the Swiss Federal Institute of Technology in Lausanne, scientists have for the first time synthesized an amino acid that can form the structure of active peptides and increase their effectiveness. The experiment showed that when an amino acid is introduced into biologically active peptides, its effectiveness can be increased by more than 40 times. With this result, a series of new drugs are expected to be developed.

The corresponding papers are published in the journal Nature chemistry. Currently, drugs mainly consist of two types of substances, one of which is a polypeptide substance of natural origin, and the other is a protein. Although there are many types of peptides and proteins, there are only 20 types of natural amino acids. Each amino acid has a different structure and chemical properties, and the combination of different amino acids has led to different properties and functions of peptides and proteins. Until recently, the vast majority of amino acid-based drugs were also used in the original nature of amino acids, such as hormones, insulin, antibiotics, cyclosporine, etc..

However, due to the emergence of many new diseases and the evolution of the original bacteria, viruses, scientists need to develop new, more effective drugs. One of the ways to meet this demand is directed evolution, i.e. modeling the development of nature in the laboratory and developing new peptides and proteins.

At the Federal Institute of Technology in Lausanne, Christian Hines led a research team to develop the synthesis of an amino acid whose unique structure can significantly increase the therapeutic effectiveness of peptides and proteins. This synthetic amino acid is very similar to the natural amino acid known as cysteine. Cysteine, like other natural amino acids, does not have a sulfur group, which allows it to combine with other cysteine to form a new structure, thereby affecting the functions of peptides and proteins. For the first time, the researchers developed 5 similar amino acids of cysteine, and integrated them into the structure of two types of bioactive peptides, one of which can inhibit cancer-related enzymes, the other-block neuronal receptors..

Tests have shown that compared with traditional drugs, the activity of the new drug is almost 40 times higher. Hayes said: ‘This is very surprising. Usually, if you touch natural molecules, you can only make it worse. In this case, we found that, on the contrary, we get the desired results.’ In the course of our research, we found that the diversity of the structure of the peptide library is the key to achieving a good combination and better results.’ With this new amino acid, you can create very diverse peptide structures.’

It is believed that bicyclic peptides can replace small molecules or antibodies used in conventional drugs for the treatment of diseases. New therapeutic peptides will play an important role in drug development in the future. Hayes says that they have developed the use of bicyclic peptides to create drugs for treating various diseases, and the next step is to use this new amino acid in directed evolutionary experiments.